Section 7: Post Congress additions最新文献

英文中文

4CPS-191 Switch to benralizumab for severe eosinophilic asthma 4CPS-191切换到benralizumab治疗严重嗜酸性哮喘

Section 7: Post Congress additions

Pub Date : 2022-03-01 DOI: 10.1136/ejhpharm-2022-eahp.403

M. Gutiérrez Lorenzo, L. Rodríguez De Francisco, J. Romero Puerto, P. Ciudad Gutiérrez, P. del Valle Moreno

引用次数: 0

5PSQ-054 Endophthalmitis after intravitreal injection with anti-angiogenic drugs: a rare but serious complication 玻璃体内注射抗血管生成药物后眼内炎:罕见但严重的并发症

Section 7: Post Congress additions

Pub Date : 2022-03-01 DOI: 10.1136/ejhpharm-2022-eahp.420

C. Aparicio Carreño, A. Gándara Ande, A. Fórneas Sangil, B. Fernández González, A. Ayastuy Ruiz, R. Pampín Sánchez, C. Martínez-Múgica Barbosa, A. Fernández González

引用次数: 0

4CPS-129 Adjust doses of antibiotics in patients with renal insufficiency 调整肾功能不全患者的抗生素剂量

Section 7: Post Congress additions

Pub Date : 2022-03-01 DOI: 10.1136/ejhpharm-2022-eahp.395

R. Castillejo, A. Aguado Paredes, A. Martinez Suarez, L. Moñino Domínguez, L. Martín Casado, M. Romero González

引用次数: 0

4CPS-105 Cardiovascular risk factors in patients with HIV infection with antiretroviral treatment 接受抗逆转录病毒治疗的HIV感染患者的心血管危险因素

Section 7: Post Congress additions

Pub Date : 2022-03-01 DOI: 10.1136/ejhpharm-2022-eahp.393

A. Fernández González, C. Aparicio Carreño, A. Gándara Ande, A. Fórneas Sangil, S. Fuertes Camporro, J. Fra Yáñez

引用次数: 0

4CPS-152 Characterisation of a compounded voriconazole solution for nebulisation and description of its use in the clinical setting 4CPS-152雾化用复方伏立康唑溶液的特性及其在临床应用的描述

Section 7: Post Congress additions

Pub Date : 2022-03-01 DOI: 10.1136/ejhpharm-2022-eahp.399

M. Larrosa García, S. Terradas Campanario, A. Fernández Polo, C. Cañete Ramírez, A. Pau Parra, L. Doménech Moral, D. Campany Herrero, MR Gomez Domingo, M. G. Gorgas Torner

引用次数: 0

4CPS-091 Analysis of pharmaceutical interventions related to high-risk-drugs in the emergency department 4CPS-091急诊科高危药物相关药物干预分析

Section 7: Post Congress additions

Pub Date : 2022-03-01 DOI: 10.1136/ejhpharm-2022-eahp.390

L. Rico-Pizarro, L. Moreno-Gutiérrez, C. Puivecino-Moreno, Y. Castellanos-Clemente, Mdm García-Gutiérrez, N. Font-Tarres, M. García-Gil

Background and importance Medication errors are frequent in the emergency department (ED) and the most common drugs involved are high-risk-drugs (HRD), which are drugs that are more likely to cause serious or even fatal harm to patients when used incorrectly. Aim and objectives Describe the evolution of pharmaceutical interventions in the ED related to HRD in two comparable time periods and evaluate the acceptance degree. Material and methods Retrospective observational study. All interventions performed in the ED during the periods between July and December 2019 and 2020 were included. The primary endpoint was the percentage of interventions related to HRD and their acceptance percentage. Secondary endpoints were: percentage of interventions related to HRD according to therapeutic group, 2 their acceptance percentage, and the main reasons for intervention (>15%). Interventions were recorded through the electronic prescription programme and were communicated to the responsible physician. The data were processed using Excel 2013. Results A total of 165/494 (33.4%) and 234/731 (32.0%) HRD interventions were performed in 2019 and 2020, respectively. The acceptance percentages were 108/165 (65.5%) and 173/234 (73.9%). The main HRD therapeutic groups on which we intervened and their acceptance percentage in the periods of 2019 and 2020, respectively, were: heparin and parenteral anticoagulants (23.6% (61.5%) and 20.1% (83.0%)), insulins (12.1% (60.0%) and 15.0% (71.4%)), oral anticoagulants (10.9% (66.7%) and 13.2% (83.9%)), opioids (8.5% (71.4%) and 7.7% (77.8%), antipsychotics (7.9% (69.2%) and 6.8% (68.8%)), diuretics (7.3% (50.0%) and 16.7% (61.5%)), sedatives (6.7% (63.6%) and 4.3% (90.0%)), antibiotics (6.1% (80.0%) and 1.3% (100%)), narrow-margin antiepileptics (4.2% (71.4%) and 5.6% (69.2%)) and other groups (<5%). The main intervention reasons (>15%) on the most prevalent therapeutic groups (>10%) were in the 2019 and 2020 periods, respectively: heparin and parenteral anticoagulants (need for treatment (66.7% and 57.4%)); insulins (need for treatment (60.0% and 41.2%), medication reconciliation (15.0% and 23.5%), inadequate dose (10.0% and 17.6%)); oral anticoagulants (medication reconciliation (55.6% and 41.9%), inadequate dose (11.1% and 19.4%)); diuretics (medication reconciliation (50.0% and 43.6%) and renal insufficiency (16.7% and 12.8%)). Conclusion and relevance The percentage of interventions related to HRD was similar in both periods; however, there was an increase in acceptance degree in the 2020 period. More than a half of HRD interventions were performed on parenteral heparin, insulins, oral anticoagulants, and diuretics. The most prevalent reasons for intervention were the need for additional treatment and medication reconciliation. It seems that the intervention of pharmacists in the ED could improve the safety in the use of HRD.

背景与重要性在急诊科(ED)中用药错误是常见的，其中最常见的药物是高风险药物(high-risk drug, HRD)，这些药物在使用不当时更容易对患者造成严重甚至致命的伤害。目的和目标描述在两个可比较的时间段内与HRD相关的ED药物干预的演变，并评估其接受程度。材料与方法回顾性观察研究。纳入了2019年7月至12月至2020年期间在急诊科实施的所有干预措施。主要终点是与HRD相关的干预措施的百分比及其接受率。次要终点为:治疗组与HRD相关的干预措施百分比、接受率和干预的主要原因(>15%)。通过电子处方程序记录干预措施，并传达给负责的医生。数据使用Excel 2013进行处理。结果2019年和2020年分别实施了165/494(33.4%)和234/731(32.0%)例HRD干预。合格率分别为108/165(65.5%)和173/234(73.9%)。2019年和2020年我们干预的主要HRD治疗组及其接受率分别为:肝素钠和注射用药物的抗凝血剂(23.6%(61.5%)和20.1%(83.0%)、胰岛素(12.1%(60.0%)和15.0%(71.4%),口服抗凝血剂(10.9%(66.7%)和13.2%(83.9%),阿片类药物(8.5%(71.4%)和7.7%(77.8%),抗精神病药物(7.9%(69.2%)和6.8%(68.8%),利尿剂(7.3%(50.0%)和16.7%(61.5%),镇静剂(6.7%(63.6%)和4.3%(90.0%),抗生素(6.1%(80.0%)和1.3% (100%),窄缘抗癫痫药(4.2%(71.4%)和5.6%(69.2%))和其他组(15%)上最流行的治疗组(>10%)分别是在2019年和2020年期间:肝素和肠外抗凝剂(需要治疗(66.7%和57.4%));胰岛素(需要治疗(60.0%和41.2%)、药物调节(15.0%和23.5%)、剂量不足(10.0%和17.6%));口服抗凝剂(药物调和(55.6%和41.9%)，剂量不足(11.1%和19.4%));利尿剂(药物调和(50.0%和43.6%)和肾功能不全(16.7%和12.8%))。结论和相关性两个时期与HRD相关的干预措施百分比相似;然而，在2020年期间，接受程度有所增加。超过一半的HRD干预是通过肠外肝素、胰岛素、口服抗凝剂和利尿剂进行的。干预最普遍的原因是需要额外的治疗和药物调节。药师在急诊科的干预可以提高HRD使用的安全性。

{"title":"4CPS-091 Analysis of pharmaceutical interventions related to high-risk-drugs in the emergency department","authors":"L. Rico-Pizarro, L. Moreno-Gutiérrez, C. Puivecino-Moreno, Y. Castellanos-Clemente, Mdm García-Gutiérrez, N. Font-Tarres, M. García-Gil","doi":"10.1136/ejhpharm-2022-eahp.390","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.390","url":null,"abstract":"Background and importance Medication errors are frequent in the emergency department (ED) and the most common drugs involved are high-risk-drugs (HRD), which are drugs that are more likely to cause serious or even fatal harm to patients when used incorrectly. Aim and objectives Describe the evolution of pharmaceutical interventions in the ED related to HRD in two comparable time periods and evaluate the acceptance degree. Material and methods Retrospective observational study. All interventions performed in the ED during the periods between July and December 2019 and 2020 were included. The primary endpoint was the percentage of interventions related to HRD and their acceptance percentage. Secondary endpoints were: percentage of interventions related to HRD according to therapeutic group, 2 their acceptance percentage, and the main reasons for intervention (>15%). Interventions were recorded through the electronic prescription programme and were communicated to the responsible physician. The data were processed using Excel 2013. Results A total of 165/494 (33.4%) and 234/731 (32.0%) HRD interventions were performed in 2019 and 2020, respectively. The acceptance percentages were 108/165 (65.5%) and 173/234 (73.9%). The main HRD therapeutic groups on which we intervened and their acceptance percentage in the periods of 2019 and 2020, respectively, were: heparin and parenteral anticoagulants (23.6% (61.5%) and 20.1% (83.0%)), insulins (12.1% (60.0%) and 15.0% (71.4%)), oral anticoagulants (10.9% (66.7%) and 13.2% (83.9%)), opioids (8.5% (71.4%) and 7.7% (77.8%), antipsychotics (7.9% (69.2%) and 6.8% (68.8%)), diuretics (7.3% (50.0%) and 16.7% (61.5%)), sedatives (6.7% (63.6%) and 4.3% (90.0%)), antibiotics (6.1% (80.0%) and 1.3% (100%)), narrow-margin antiepileptics (4.2% (71.4%) and 5.6% (69.2%)) and other groups (<5%). The main intervention reasons (>15%) on the most prevalent therapeutic groups (>10%) were in the 2019 and 2020 periods, respectively: heparin and parenteral anticoagulants (need for treatment (66.7% and 57.4%)); insulins (need for treatment (60.0% and 41.2%), medication reconciliation (15.0% and 23.5%), inadequate dose (10.0% and 17.6%)); oral anticoagulants (medication reconciliation (55.6% and 41.9%), inadequate dose (11.1% and 19.4%)); diuretics (medication reconciliation (50.0% and 43.6%) and renal insufficiency (16.7% and 12.8%)). Conclusion and relevance The percentage of interventions related to HRD was similar in both periods; however, there was an increase in acceptance degree in the 2020 period. More than a half of HRD interventions were performed on parenteral heparin, insulins, oral anticoagulants, and diuretics. The most prevalent reasons for intervention were the need for additional treatment and medication reconciliation. It seems that the intervention of pharmacists in the ED could improve the safety in the use of HRD.","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"19 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132534258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

3PC-032 Optimising analgosedation in the intensive care unit during the SARS-CoV-2 pandemic 优化SARS-CoV-2大流行期间重症监护病房的镇痛作用

Section 7: Post Congress additions

Pub Date : 2022-03-01 DOI: 10.1136/ejhpharm-2022-eahp.379

I. Garcia del Valle, M. Sanmartín Suñer, L. Val Prat, M. Nevot Blanc, P. Marcos Pascua, G. Morla Clavero, M. Garcia Pelaez, G. Baronet Jordana

Background and importanceThe pandemic caused by SARS-CoV-2 evidenced the need for expediting the dispensation and usage process, poorly automated, of narcotic drugs and for optimising the most commonly used perfusions available in the hospital (midazolam, dexmedethomidine, propofol, fentanyl). With this intervention, significant improvements in efficacy and safety were expected, considering the fact that perfusions decrease the risk of infection, medication errors and the workload and exposure of nurses.Aim and objectivesTo elaborate a physicochemical and microbiological stable fentanyl perfusion and to adapt the presentations of drugs (midazolam, dexmedethomidine, propofol, fentanyl) used for analgosedation in COVID-19 patients admitted to the intensive care unit (ICU).Material and methodsA multidisciplinary team formed by intensive care doctors, nurses and clinical pharmacists was created in October 2020 to discuss areas of improvement and effort optimisation.All midazolam and propofol presentations were changed for others of larger volume available on the market. A dexmedethomidine perfusion 2000 mg/250 mL was standardised thanks to previous stability data collected.A new fentanyl perfusion was prepared and validated in sterile conditions after a literature systematic review, microbiological controls in tryptic soy broth (TSB) and thioglycollate broth, and a microbiological risk matrix were done.Fentanyl perfusions were stocked in Pharmacy and individually dispensed according to the infusion speed of each patient. Control numbers were assigned to every preparation to maintain the narcotics’ traceability.ResultsEach perfusion consisted of 1500 μg fentanyl (10 vials 150 μg/3 ml=1 perfusion) diluted in 100 mL sodium chloride 0.9%. The final stability given was 30 days at room temperature (all culture replicates in TSB and thioglycollate broth at days 0, 9 and 30 were negative). The daily number of preparations depended on the epidemiology of the disease. However, a median value of 13 perfusions was dispensed up to a total of 21 ICU beds.Conclusion and relevanceThis model can be extrapolated to other Pharmacy Services as long as volumetric pumps, trained professionals and horizontal laminar flow cabinets are available. The intervention met some of the demands created during the pandemic and helped to slightly attenuate the pressure on healthcare professionals.References and/or acknowledgementsConflict of interestNo conflict of interest

背景和重要性SARS-CoV-2引起的大流行证明有必要加快麻醉药品的分配和使用流程(自动化程度较低)，并优化医院最常用的输液(咪达唑仑、右美托咪定、异丙酚、芬太尼)。考虑到输液降低了感染、用药错误的风险以及护士的工作量和暴露，这种干预措施有望显著改善疗效和安全性。目的和目的探讨一种物理化学和微生物学稳定的芬太尼灌注，并适应新冠肺炎重症监护病房(ICU)患者镇痛镇静药物(咪达唑仑、右美托咪定、异丙酚、芬太尼)的使用情况。材料和方法由重症监护医生、护士和临床药剂师组成的多学科团队于2020年10月成立，讨论改进和优化工作的领域。所有咪达唑仑和异丙酚的表现都被市场上其他更大的容量所改变。根据先前收集的稳定性数据，标准化右美托咪定灌注2000 mg/250 mL。通过文献系统综述、胰蛋白酶豆汤(TSB)和巯基乙酸酯肉汤的微生物对照以及微生物风险矩阵，制备了新的芬太尼灌注液，并在无菌条件下进行了验证。药房存放芬太尼输液，并根据每位患者的输液速度单独配药。为保证麻醉品的可追溯性，每种制剂都分配了控制编号。结果每次灌注1500 μg芬太尼(10瓶，150 μg/ 3ml =1次灌注)，用100 ml 0.9%氯化钠稀释。室温下的最终稳定性为30天(在TSB和巯基乙酸酯肉汤中0、9和30天的所有培养重复均为阴性)。每天的制剂数量取决于疾病的流行病学。然而，中位数为13次灌注，共分配了21个ICU床位。结论和相关性只要有容积泵、训练有素的专业人员和水平层流柜，该模型可以推广到其他药学服务。干预措施满足了大流行期间产生的一些需求，并有助于略微减轻保健专业人员的压力。参考文献和/或致谢利益冲突无利益冲突

{"title":"3PC-032 Optimising analgosedation in the intensive care unit during the SARS-CoV-2 pandemic","authors":"I. Garcia del Valle, M. Sanmartín Suñer, L. Val Prat, M. Nevot Blanc, P. Marcos Pascua, G. Morla Clavero, M. Garcia Pelaez, G. Baronet Jordana","doi":"10.1136/ejhpharm-2022-eahp.379","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.379","url":null,"abstract":"Background and importanceThe pandemic caused by SARS-CoV-2 evidenced the need for expediting the dispensation and usage process, poorly automated, of narcotic drugs and for optimising the most commonly used perfusions available in the hospital (midazolam, dexmedethomidine, propofol, fentanyl). With this intervention, significant improvements in efficacy and safety were expected, considering the fact that perfusions decrease the risk of infection, medication errors and the workload and exposure of nurses.Aim and objectivesTo elaborate a physicochemical and microbiological stable fentanyl perfusion and to adapt the presentations of drugs (midazolam, dexmedethomidine, propofol, fentanyl) used for analgosedation in COVID-19 patients admitted to the intensive care unit (ICU).Material and methodsA multidisciplinary team formed by intensive care doctors, nurses and clinical pharmacists was created in October 2020 to discuss areas of improvement and effort optimisation.All midazolam and propofol presentations were changed for others of larger volume available on the market. A dexmedethomidine perfusion 2000 mg/250 mL was standardised thanks to previous stability data collected.A new fentanyl perfusion was prepared and validated in sterile conditions after a literature systematic review, microbiological controls in tryptic soy broth (TSB) and thioglycollate broth, and a microbiological risk matrix were done.Fentanyl perfusions were stocked in Pharmacy and individually dispensed according to the infusion speed of each patient. Control numbers were assigned to every preparation to maintain the narcotics’ traceability.ResultsEach perfusion consisted of 1500 μg fentanyl (10 vials 150 μg/3 ml=1 perfusion) diluted in 100 mL sodium chloride 0.9%. The final stability given was 30 days at room temperature (all culture replicates in TSB and thioglycollate broth at days 0, 9 and 30 were negative). The daily number of preparations depended on the epidemiology of the disease. However, a median value of 13 perfusions was dispensed up to a total of 21 ICU beds.Conclusion and relevanceThis model can be extrapolated to other Pharmacy Services as long as volumetric pumps, trained professionals and horizontal laminar flow cabinets are available. The intervention met some of the demands created during the pandemic and helped to slightly attenuate the pressure on healthcare professionals.References and/or acknowledgementsConflict of interestNo conflict of interest","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"64 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116316130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

6ER-013 Analysis of patients’ mortality in SARS-CoV-2 infection during the first month of hospital admission 6ER-013 SARS-CoV-2感染患者入院第一个月死亡率分析

Section 7: Post Congress additions

Pub Date : 2022-03-01 DOI: 10.1136/ejhpharm-2022-eahp.431

R. Castillejo, J. Cordero, M. Romero-González, A. Martinez-Suarez

Background and importanceAs of December 2019, the world is facing a pandemic caused by the SARS-CoV-2 coronavirus (COVID-19). Symptoms resulting from the infection vary widely, ranging from asymptomatic disease to pneumonia and life-threatening complications.Aim and objectivesThe aim was to study the impact of the active oncohaematological process on the severity and short-medium term mortality of COVID-19 infection.Material and methodsObservational retrospective study, carried out in a Spanish tertiary-level hospital. All patients diagnosed with COVID-19 and hospital admission between March 2020 and June 2021 were included. Variables collected were demographics, comorbidities;situation during hospitalisation (defining severe situation as admission to intensive care unit (ICU) or intubation) and mortality at 14 and 30 days after hospital admission. Data were obtained through the digital medical record and managed by R software (V.4–2021).ResultsWe included 1924 patients in the non-oncological group, 47.5% (915) men with a median age of 67 years and interquartile range (IQR) of 53–77. 128 patients (6.23%) were included in the active oncohaematological group, 58.6% were men (median age 72 (IQR 63–78) years). The most prevalent oncohaematological processes were: lung cancer (16.4%), colorectal (15.6%), bladder (10.9%), breast (10.2%) and prostate (8.59%). Metastases were present in 42.2% of patients. The main comorbidities presented by oncohaematological patients with statistical significance versus non-oncological patients were diabetes mellitus (30.5% vs 19.4%), dyslipidaemia (46.9% vs 32.2%), hypertension (52.3% vs 42.0%), chronic renal failure (18.0% vs 8.73%), chronic obstructive pulmonary disease (22.7% vs 9.94%), obesity (14.1% vs 15.2%) and heart failure (13.3% vs 10.6%). In the oncohaematological group, 44.5% were in a serious condition during their admission. The number who died compared to non-oncohaematological patients was 23.4% versus 13.6% at day 14 and 29.7% versus 18.1% at day 30. The two main neoplasms in the deceased patients were lung cancer (26.3%) and colorectal cancer (21%). Univariate analysis showed a relative risk of 1.72 (1.23–2.4) and 1.64 (1.23–2.17) mortality at 14 and 30 days, respectively, for COVID-19 in patients with active oncohematological processes versus non-oncohematological processes.Conclusion and relevanceThe data reflect a higher mortality at 14 and 30 days due to COVID-19 in the oncohaematological population (72% and 64%, respectively). The oncohaematological population has a higher percentage of comorbidities associated with the total that may also influence this increased risk of mortality.References and/or acknowledgementsConflict of interestNo conflict of interest

背景及重要性截至2019年12月，世界正面临由新冠肺炎(COVID-19)引起的大流行。感染引起的症状差别很大，从无症状疾病到肺炎和危及生命的并发症。目的和目的研究活动性肿瘤血液学过程对COVID-19感染严重程度和中短期死亡率的影响。材料与方法观察性回顾性研究，在西班牙一家三级医院进行。所有在2020年3月至2021年6月期间被诊断为COVID-19并住院的患者都被纳入其中。收集的变量包括人口统计学、合并症、住院期间的情况(将严重情况定义为入住重症监护病房(ICU)或插管)以及入院后14天和30天的死亡率。数据通过数字病历获取，并由R软件(V.4-2021)管理。结果我们纳入了1924例非肿瘤组患者，其中47.5%(915例)为男性，中位年龄为67岁，四分位间距(IQR)为53-77。活动性血液肿瘤组128例(6.23%)，58.6%为男性(中位年龄72岁(IQR 63-78)岁)。最常见的肿瘤血液学病变为:肺癌(16.4%)、结直肠癌(15.6%)、膀胱癌(10.9%)、乳腺癌(10.2%)和前列腺癌(8.59%)。42.2%的患者存在转移。与非肿瘤患者相比，血液肿瘤患者出现的主要合并症为糖尿病(30.5% vs 19.4%)、血脂异常(46.9% vs 32.2%)、高血压(52.3% vs 42.0%)、慢性肾功能衰竭(18.0% vs 8.73%)、慢性阻塞性肺疾病(22.7% vs 9.94%)、肥胖(14.1% vs 15.2%)和心力衰竭(13.3% vs 10.6%)。在血液肿瘤组中，44.5%的患者入院时病情严重。与非血液肿瘤患者相比，第14天和第30天的死亡人数分别为23.4%和13.6%和29.7%和18.1%。死亡患者的两种主要肿瘤是肺癌(26.3%)和结直肠癌(21%)。单因素分析显示，活动性血液肿瘤过程患者与非血液肿瘤过程患者在14天和30天死亡的相对风险分别为1.72(1.23-2.4)和1.64(1.23-2.17)。数据显示，在血液肿瘤患者中，COVID-19在14天和30天的死亡率较高(分别为72%和64%)。血液病人群的合并症比例较高，这也可能影响死亡风险的增加。参考文献和/或致谢利益冲突无利益冲突

{"title":"6ER-013 Analysis of patients’ mortality in SARS-CoV-2 infection during the first month of hospital admission","authors":"R. Castillejo, J. Cordero, M. Romero-González, A. Martinez-Suarez","doi":"10.1136/ejhpharm-2022-eahp.431","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.431","url":null,"abstract":"Background and importanceAs of December 2019, the world is facing a pandemic caused by the SARS-CoV-2 coronavirus (COVID-19). Symptoms resulting from the infection vary widely, ranging from asymptomatic disease to pneumonia and life-threatening complications.Aim and objectivesThe aim was to study the impact of the active oncohaematological process on the severity and short-medium term mortality of COVID-19 infection.Material and methodsObservational retrospective study, carried out in a Spanish tertiary-level hospital. All patients diagnosed with COVID-19 and hospital admission between March 2020 and June 2021 were included. Variables collected were demographics, comorbidities;situation during hospitalisation (defining severe situation as admission to intensive care unit (ICU) or intubation) and mortality at 14 and 30 days after hospital admission. Data were obtained through the digital medical record and managed by R software (V.4–2021).ResultsWe included 1924 patients in the non-oncological group, 47.5% (915) men with a median age of 67 years and interquartile range (IQR) of 53–77. 128 patients (6.23%) were included in the active oncohaematological group, 58.6% were men (median age 72 (IQR 63–78) years). The most prevalent oncohaematological processes were: lung cancer (16.4%), colorectal (15.6%), bladder (10.9%), breast (10.2%) and prostate (8.59%). Metastases were present in 42.2% of patients. The main comorbidities presented by oncohaematological patients with statistical significance versus non-oncological patients were diabetes mellitus (30.5% vs 19.4%), dyslipidaemia (46.9% vs 32.2%), hypertension (52.3% vs 42.0%), chronic renal failure (18.0% vs 8.73%), chronic obstructive pulmonary disease (22.7% vs 9.94%), obesity (14.1% vs 15.2%) and heart failure (13.3% vs 10.6%). In the oncohaematological group, 44.5% were in a serious condition during their admission. The number who died compared to non-oncohaematological patients was 23.4% versus 13.6% at day 14 and 29.7% versus 18.1% at day 30. The two main neoplasms in the deceased patients were lung cancer (26.3%) and colorectal cancer (21%). Univariate analysis showed a relative risk of 1.72 (1.23–2.4) and 1.64 (1.23–2.17) mortality at 14 and 30 days, respectively, for COVID-19 in patients with active oncohematological processes versus non-oncohematological processes.Conclusion and relevanceThe data reflect a higher mortality at 14 and 30 days due to COVID-19 in the oncohaematological population (72% and 64%, respectively). The oncohaematological population has a higher percentage of comorbidities associated with the total that may also influence this increased risk of mortality.References and/or acknowledgementsConflict of interestNo conflict of interest","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"20 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114827732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

4CPS-255 Frequency of consumption of complementary and alternative medicine among HIV patients: a multicentre cross-sectional study 艾滋病患者使用补充和替代药物的频率:一项多中心横断面研究

Section 7: Post Congress additions

Pub Date : 2022-03-01 DOI: 10.1136/ejhpharm-2022-eahp.412

E. Gonzalez Colominas, M. De Antonio Cuscó, M. Masip Torne, M. Martin, G. Cardona, M. Comas, Mathieu Roch, B. Lopez, FI Torres, A. Retamero, P. Luque

引用次数: 0

4CPS-253 Differences between pharmaceutical interventions performed on antimicrobials in medical and surgical services 医疗和外科服务中抗菌素药物干预的差异

Section 7: Post Congress additions

Pub Date : 2022-03-01 DOI: 10.1136/ejhpharm-2022-eahp.411

S. Fernández, S. Ortonobes, N. Soler, M. Florit

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Section 7: Post Congress additions

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀